Supplements

WHAT THE EVIDENCE SAYS

The starting point is solid and uncontested: gut bacteria help shape the response to immune checkpoint blockade ^[1][3]. The controversy begins with the practical question — whether that relationship can be exploited by swallowing a capsule.

The key clinical paper appeared in Science in 2021 (Spencer et al., PMID 34941392) ^[1]. It assessed faecal microbiota profiles, dietary habits and use of commercially available probiotic supplements in melanoma patients receiving immunotherapy, alongside parallel preclinical work ^[1]. The authors report: "Higher dietary fiber was associated with significantly improved progression-free survival in 128 patients on ICB, with the most pronounced benefit observed in patients with sufficient dietary fiber intake and no probiotic use ^[1]." In mouse models the same picture was reproduced: a low-fibre diet or probiotic administration impaired the response to anti-PD-1-based therapy, with a lower frequency of interferon-gamma-positive cytotoxic T cells in the tumour microenvironment ^[1].

The picture is not uniform, however, and honesty requires the other side. A 2025 review (Frontiers in Immunology, PMID 41472726) collects data in which specific strains — Bifidobacterium, Lactobacillus, Clostridium butyricum, Akkermansia muciniphila — enhanced checkpoint inhibitor responses in animal models of melanoma, lung and colorectal cancer, while in early-phase clinical studies and retrospective cohorts, particularly in lung and renal cancer, probiotic use was associated with improved progression-free and overall survival ^[2]. The same authors state the limitation plainly: "most clinical data are observational, and the field lacks standardized probiotic formulations and dosing protocols ^[2]."

The second, far better established part of this topic is ANTIBIOTICS. The National Cancer Institute describes a European study as follows: "Patients who had taken antibiotics for an infection within 2 months before or 1 month after starting immunotherapy with checkpoint inhibitors did not live as long as patients who didn't take antibiotics ^[3]." A caveat must accompany that sentence: this is an observation, not an instruction to forgo antibiotics. Infection in a cancer patient can be life-threatening, and only the treating physician decides whether antibiotic therapy is warranted.

STRENGTH OF THE EVIDENCE

Low to moderate — and unevenly distributed. The association between microbiota composition and immunotherapy efficacy is well documented. The claim that taking a probiotic improves treatment outcomes is supported by NOT ONE conclusive randomised trial; the available clinical data are observational and therefore burdened by the fact that people who reach for supplements differ from those who do not in many ways at once ^[2]. Moreover, two good sources point in opposite directions — the Science paper signals possible harm, the 2025 review possible benefit ^[1][2]. In that situation the only honest answer is "we do not know", rather than picking whichever side sounds more agreeable.

WHO THIS ENTRY IS FOR

For patients treated with checkpoint inhibitors (most often in melanoma, lung cancer and renal cancer) and their families, who encounter reports that "the microbiome decides whether immunotherapy works" and wonder whether to buy a probiotic. It does not cover probiotics used for other indications under medical supervision, nor faecal microbiota transplantation, which remains an investigational procedure conducted only within clinical trials.

INTERACTIONS WITH CANCER TREATMENT

First — possible weakening of immunotherapy. The Science paper indicates that in melanoma patients taking probiotics the benefit of high fibre intake was less pronounced, and animal models showed an outright worse response to anti-PD-1 after probiotic administration ^[1]. This is a signal, not proof, but a signal pointing toward harm in a treatment that for many patients is the only effective option.

Second — infection risk. Probiotic strains are live microorganisms, and bloodstream infections caused by those very strains have been described in immunocompromised people ^[4][5]. A case series in Emerging Infectious Diseases (2024) on Clostridium butyricum bacteraemia after probiotic use noted that most patients had compromised immune systems ^[4]. In another series in the same journal (2026), among 5,034 children who received probiotics after cardiac surgery, 6 developed bacteraemia with a probiotic strain; all had central venous catheters ^[5]. The population differs from an oncological one, but the mechanism — translocation of live bacteria from the gut and catheter contamination — is the same, and patients on chemotherapy combine both risk factors: neutropenia and a vascular port. Saccharomyces fungaemia after administration of an S. boulardii preparation has also been described.

Third — antibiotics. As above: the association with shorter survival is documented, but the practical conclusion is "tell your treating team that you are starting immunotherapy", not "avoid antibiotics" ^[3].

WHAT THIS MEANS FOR DIET

The only element of this topic backed by clinical data suggesting benefit is DIETARY FIBRE from food, not a supplement from the pharmacy ^[1]. That is consistent with the catalogue entry on the Mediterranean diet, and the two entries are worth reading together.

THE SCOPE OF WHAT WE WRITE HERE

We give no strains, doses or regimens, because no standardised preparation of demonstrated efficacy exists, and naming a specific one would amount to advice for an individual ^[2]. We do not describe faecal microbiota transplantation beyond noting that it is investigational. cancer3.ai is an information portal — whether to take any supplement during cancer treatment is decided by the treating team.

Sources

1. Spencer CN et al. — Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response, Science 2021: europepmc.org ↗
2. Jani CT et al. — Leveraging beneficial microbiome-immune interactions via probiotic use in cancer immunotherapy, Frontiers in Immunology 2025: europepmc.org ↗
3. National Cancer Institute — Gut Bacteria Influence Effectiveness of a Type of Immunotherapy, Cancer Currents Blog 2018: cancer.gov ↗
4. Sada RM et al. — Clostridium butyricum Bacteremia Associated with Probiotic Use, Japan, Emerging Infectious Diseases 2024: europepmc.org ↗
5. Wang X et al. — Case Series of Bacteremia Associated with Probiotic Use in Children after Cardiac Surgery, China, Emerging Infectious Diseases 2026: europepmc.org ↗